Indo Borax Reports 16% Growth in H1 FY27 Operating Income to ₹129.29 Crore

manufacturing-news
Image Courtesy: Indo Borax & Chemicals Limited

Indo Borax & Chemicals Limited (BSE: 524342; NSE: INDOBORAX), one of India’s leading manufacturers of boron-based chemicals, reported a 16% year-on-year increase in consolidated operating income to ₹129.29 crore for the half year ended September 30, 2026, compared with ₹111.42 crore in H1 FY26. Consolidated profit after tax (PAT) for H1 FY27 stood at ₹21.00 crore, against ₹26.47 crore in the corresponding period last year.

Adjusted EBITDA margin and PAT margin for the half year stood at 21.7% and 15.4%, respectively. For Q2 FY27, consolidated operating income increased to ₹58.94 crore from ₹57.85 crore in Q2 FY26. Consolidated EBITDA stood at ₹7.93 crore, while PAT was ₹4.75 crore. EBITDA margins were impacted by higher raw material costs arising from global supply chain challenges. The quarterly PAT also included expenses of ₹6.64 crore related to the acquisition of Kronox Lab Sciences Limited as a subsidiary.

Commenting on the performance, Suresh Kalra, Managing Director and CEO, Indo Borax & Chemicals Limited, said, “The quarter under review witnessed steady demand across our key product segments, despite the seasonal impact of the monsoon. However, profitability remained under pressure due to higher raw material costs and geopolitical uncertainties in the Middle East, thereby impacting the overall cost environment. We will continue to focus on operational efficiencies, prudent cost management and optimising product mix to navigate these challenges in the coming quarters.”

He added that the quarter also saw progress in the strategic integration of Kronox Lab Sciences, with synergies being stabilised across distribution markets and procurement. The company expects to sustain its growth momentum and strengthen margins through diversification, premiumisation and disciplined execution.

In another corporate development, the company’s Board has approved the amalgamation of its wholly owned subsidiary, Indoborax Infrastructure Private Limited, with Indo Borax & Chemicals Limited, subject to approvals from the National Company Law Tribunal (NCLT) and other regulatory authorities.

Commenting on the proposed amalgamation, Mr Kalra said, “We expect the proposed amalgamation to unlock greater operational efficiencies by enabling the pooling and optimal utilisation of resources across the combined entity. It will also facilitate sharper management focus, simplify governance structures and enable more agile decision-making, thereby creating a more integrated and efficient organisation.”

Established in 1980, Indo Borax & Chemicals Limited is a leading Indian manufacturer of boron-based chemicals and a recognised name in the boric acid industry. The company holds an FDA licence for manufacturing pharmaceutical-grade Boric Acid in accordance with the Indian Pharmacopoeia. Its manufacturing facility at Pithampur, Madhya Pradesh, produces Boric Acid, Disodium Octaborate Tetrahydrate (DOT) and Borax. Indo Borax was also the first company in India to receive a BIS licence for manufacturing technical-grade Boric Acid.